Lilly has set a price of $32,000 per year for Kisunla, which is higher than the top-line price of $26,500 for Leqembi. However, according to the company, it could reduce the overall cost of treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback